Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

41.36 +0.08 (+0.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
31 32 Next >
Beat the Dow Jones With CRISPR Therapeutics Stock
If approved, CRISPR's first product may deliver blockbuster sales. 
Via The Motley Fool
These 2 Biotech Stocks Could Soar in the Next Bull Market
They're both at the cutting edge of gene-editing technology. 
Via The Motley Fool
3 Prime Healthcare Takeover Targets
These three companies are attractive targets for their potential. 
Via The Motley Fool
The Best Stocks To Invest $5,000 in Right Now
The time is right for each of these great stocks. 
Via The Motley Fool
These Cheap Growth Stocks Could Supercharge Your Portfolio
All of these players are cheap today considering their growth potential. 
Via The Motley Fool
Top CRISPR Stocks
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
The gene-editing business has loads of potential, but is it enough to make you rich? 
Via The Motley Fool
Ready to Buy the Dip? Consider This Gene Editing Stock
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back. 
Via The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Right Now?
The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains? 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Patience will pay off with these two stocks. 
Via The Motley Fool
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals. 
Via The Motley Fool
Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.
CRISPR shares are ripe for a rebound after dropping 46% last year. 
Via The Motley Fool
1 Beaten-Down Stock That Has a Lot to Prove in 2023
This biotech looks like a high-risk, high-reward play. 
Via The Motley Fool
3 Top Stocks to Buy If There Is a Market Pullback
All three of these stocks performed well as the market fell in 2022. 
Via The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
3 No-Brainer Growth Stocks to Buy in 2023
These stocks all fell by double digits last year. 
Via The Motley Fool
Why Editas Medicine's Shares Jumped This Week
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool
Is Editas Medicine Stock a Buy Now?
Layoffs and a thin clinical-stage pipeline aren't very encouraging. 
Via The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist. 
Via InvestorPlace
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?
Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case? 
Via InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a 
Via Benzinga
3 Things About CRISPR Therapeutics That Smart Investors Know
The gene-therapy specialist's near-term outlook is quite bullish. 
Via The Motley Fool
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies. 
Via The Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback